Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7615691 | 1.00 | HTR1A (0.54) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL7618009 | 0.99 | HTR1A (0.55) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL7617997 | 0.99 | HTR1A (0.55) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL7860685 | 0.94 | HTR1A (0.51) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL7857029 | 0.93 | HTR1A (0.52) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL7859098 | 0.92 | HTR1A (0.59) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL7857729 | 0.91 | HTR1A (0.60) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL7614925 | 0.86 | HTR1A (0.41) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL7614937 | 0.86 | HTR1A (0.41) | HTR1ADRD2DRD3HTR1DSLC6A4 | |
| SCHEMBL9065095 | 0.85 | HTR1A (0.52) | HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0822813-B1 | A COMBINATION OF A 5-HT UPTAKE INHIBITOR WITH A SELECTIVE 5-HT 1A ANTAGONIST | ASTRAZENECA AB (SE) | 2002-04-24 | — | — | EP | disclosed |
| US-5962514-A | Combination of 5-HT uptake inhibitor with a selective 5-HT1A antagonist | ASTRA AKTIEBOLAG (SE) | 1999-10-05 | — | — | US | disclosed |
| EP-0822813-A1 | A COMBINATION OF A 5-HT UPTAKE INHIBITOR WITH A SELECTIVE 5-HT 1A? ANTAGONIST | Astra Aktiebolag (SE) | 1998-02-11 | — | — | EP | disclosed |
| US-5616610-A | CENTRAL NERVOUS SYSTEM DISORDERS | ASTRA AKTIEBOLAG (SE) | 1997-04-01 | — | — | US | disclosed |
| WO-1996033710-A1 | A COMBINATION OF A 5-HT UPTAKE INHIBITOR WITH A SELECTIVE 5-HT1A ANTAGONIST | ASTRA AKTIEBOLAG (SE) | 1996-10-31 | — | — | WO | disclosed |
| EP-0725779-A1 | NOVEL (R)-5-CARBAMOYL-8-FLUORO-3-N,N-DISUBSTITUTED-AMINO-3,4-DIHYDRO-2H-1-BENZOPYRANES | Astra Aktiebolag (SE) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995011891-A1 | NOVEL (R)-5-CARBAMOYL-8-FLUORO-3-N,N-DISUBSTITUTED-AMINO-3,4-DIHYDRO-2H-1-BENZOPYRANES | ASTRA AKTIEBOLAG (SE) | 1995-05-04 | — | — | WO | disclosed |